The right drug at the right dose and right time
Digital Therapeutics platform uses predictive analytics to accelerate diagnosis and treatment of infectious diseases
Mission & Vision
At Luminacare, our mission is to help advance the diagnostics and treatment of multi-drug resistant bacterial infections.
We aim to integrate knowledge from infectious disease research, drug discovery, data modeling and software development. We build platforms that enable the physician in their treatment process.Starting with major diseases such as Tuberculosis and COPD, we plan to expand into more areas with relevant collaboration and partnerships.
Our first predictive analytics platform, Minerva, enables the rapid selection of appropriate antibiotics and dosage that helps treat the bacterial infection in hours vs days . Accelerating the diagnosis and treatment process improves patient outcomes while reducing costs.
Our strength is our collective, diverse and relevant expertise. We are biologists, data analysts, software engineers and management professionals with experience in Pharmaceutical research and health care industries. Well-versed in modeling and simulation of drug exposures and outcomes, and clinical infectious disease management.
Dr. David Howe
Co-Founder & CEO
Co-Founder & COO
Resistant bacterial infections
Our first product addresses tuberculosis (TB), multi-drug resistant TB infections and hospital-acquired infections. Using comprehensive data models, Minerva is designed to rapidly have the patient on the right antibiotic for their infection. Our platform reduces the time from days for confirmation of resistance and selection of drug to hours. Getting the patient on the appropriate drug faster, reduces severity, hospital time and costs.